GlassScriptPhysician profile
Ting A Wang-Weinman
NPI 1801107842
$3,084.10
in general payments reported to CMS, 2019-2025
24 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $514 · 2021: $502 · 2022: $466 · 2023: $635 · 2024: $370 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.12 |
| Education | $130.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.83 | 2019-2024 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $529.52 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $522.91 | 2019-2024 | Tremfya |
| Amgen INC. | $322.25 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $161.15 | 2023-2024 | Vtama |
| Pfizer INC. | $158.98 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $85.05 | 2022-2024 | Sotyktu |
| Incyte Corporation | $71.10 | 2023-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $56.56 | 2019-2022 | |
| Leo Pharma INC. | $46.56 | 2019-2021 | |
| Genzyme Corporation | $43.43 | 2021-2024 | |
| Ucb, INC. | $38.72 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $34.23 | 2019-2025 | Nemluvio |
| Kyowa Kirin, INC. | $31.66 | 2024-2025 | Poteligeo |
| Almirall LLC | $25.32 | 2023 | Seysara |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.87 | 2024 | Spevigo |
| Celgene Corporation | $22.86 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.30 | 2020 | |
| Merck Sharp & Dohme LLC | $17.24 | 2021 | |
| Duchesnay USA Incorporated | $16.55 | 2019 | |
| Dermira, INC. | $16.00 | 2019 | |
| Mayne Pharma Commercial LLC | $15.56 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting Wang-Weinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.